Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China.
Qidong Liver Cancer Institute, The First People's Hospital of Qidong, China.
Clin Gastroenterol Hepatol. 2019 May;17(6):1204-1206. doi: 10.1016/j.cgh.2018.08.019. Epub 2018 Aug 13.
Hepatitis B (HBV) infection is the leading cause of hepatocellular carcinoma (HCC) in Asia. Hepatitis B surface antigen (HBsAg) seroclearance is considered to be one of the most important end points of chronic HBV infection and is associated with a reduced risk of HCC.
乙型肝炎病毒（HBV）感染是亚洲地区肝细胞癌（HCC）的主要病因。乙型肝炎表面抗原（HBsAg）血清学清除被认为是慢性 HBV 感染的最重要终点之一，与 HCC 风险降低相关。
